In Aug 8th 2023, H&J CRO International Inc. (hereinafter referred to as “H&J”) and Fosun Health Innovative drug funding (hereinafter referred to as “Fosun”) reached strategic cooperation at this lotus blossom summer season. The strategic cooperation marks a substantial step in the cooperation between H&J and Fosun, and also it is a milestone for promoting long-term cooperation between both sides in the field of clinical trials.
The members to attend and witness the signing ceremony is shown below:CEO of Fosun Health Capital / CEO of Fosun, Innovative drug funding: Zhiping Cui, Managing Director of Fosun Innovative drug funding: Xiaohua Liu, Executive General Manager of Fosun Innovative drug funding: Cheng Xie, CEO of ConjuStar: Shuyi Tang, The founder and CEO/CSO of Starmab Biology: Maomao AN, The founder and president of H&J and President: Fanqiang Meng, CSO of H&J: Shiping Xing, BD Support Vice General Manger of H&J: Yuexia Ma, BD Marketing Executive Director of H&J：Yao Han
Innovative motivation, mutual motion
Exploring infinite possibilities of innovative drug research together
Innovative researching is the core developing power in Fosun Pharma. Fosun innovative drug funding had dedicated in innovative biopharmaceutics, Since the company was established two years ago and completed the layout in many research fields, such as anti-infective antibody development, small interfering RNA drugs, polypeptide conjugated drugs, gene therapy, cell therapy, targeted mRNA delivery, aesthetic medicine and etc. Till June 30th 2023, Fosun had initiated 2 phase I clinical trials and submitted several IND applications.
Same innovative motivation with Fosun, H&J had twenty years of experience in conducting clinical trials and providing so called “one way to destiny”innovative drug full CRO services. Till now, more than 1,000 clinical trials have been undertaken by H&J.
Fosun and H&J reached a long-term ecological strategic partner based on the same strategy and wishes, having mutual recognition, and trusting of each other's resource advantages and cooperation modes. Both sides will be in accordance with the principles of complementary advantages, resource sharing, quality and efficiency improvement and win-win cooperation.
Based on the strategic cooperation with Fosun, H&J will provide services including but not limited to Phase 1-3 clinical trial protocol design, coordinating clinical trials, site monitoring, project management, medical monitoring, project audit, pharmacovigilance, patient recruitment, data management, statistic analysis, NDA application services and etc. H&J will provide professional advice on the rationality of clinical plan of product development, analysis and judgment of probability of drug conversion, and potential market space of products, and also promote investment cooperation and create an ecosystem of innovative drug investment and business cooperation. Moreover, both sides will integrate their respective advantages in technology, market and talent, jointly embrace the development trend and technological change of biomedicine, promote the parties to move towards a deeper, higher level and wider field, and explore the infinite possibilities of new drug research and development.
As Cuizhi Ping, CEO of Fosun innovative drug funding and Fosun health capical, said,“In recent years, Fosun had dedicated in the high value innovative research filed, such as gene therapy, cell therapy, siRNA. H&J is highly matched with Fosu’s requirement in providing “one way to destiny”CRO full services. This partnership provides a strong complementary resource to Fosun and enables us to go more forward, more stable and more long-term on the road of internationalization."
As Fanqiang Meng, CEO and President of H&J，said, “H&J is very proud to enter into a strategic partnership with Fosun. As per the innovative drugs, being fast to complete clinical trials and successful listing is the essential element to seize the opportunity in the market competition. H&J will devote efforts and energy to design and operate each clinical trial project. Of particular concern is the importance of striking a balance between toxicity and efficacy in Phase I clinical trials of innovative drugs. We should pay close attention to AE (such as bone marrow suppression, fever, elevated blood pressure, etc.) to ensure the safety of subjects. In the process of Phase I clinical trial, we will be equipped with a professional medical team to focus on the safety data of the subjects and escort the project landing well.”
About Fosun
Fosun Health Innovative Drug Funding is the first VC fund in the field of new drugs initiated and established by Fosun Pharma. The fund mainly invests in early-stage and expansion projects in the field of biomedicine-based health with technological innovation and rapid growth potential and is committed to incubating high-quality projects in universities and research institutes, as well as bringing overseas leading technologies and products in the field of biotechnology to China through introduction and cooperation. In present, the company list of being incubated and invested by Fosun is shown below:
1. Starmab Biologics (Suzhou) Co.,Ltd. ; 2. Suzhou Biomissile Pharmaceuticals Co., Ltd.; 3.Suzhou Hepa Thera Biopharmaceutical Co., Ltd.; 4.UgeneX Therapeutics Co., Ltd. ; 5. Otovia Therapeutics; 6. DSci Lab Co., LTD; 7. JuveStar Co., LTD; 8. ConjuStar Co., LTD ; 9. Tianjin Xingsiyi Biotechnology Co., LTD; 10. Celregen Therapeutic Co., LTD
About H&J
H&J was founded in 2003 by Dr. Uriel Halbreich, a famous American professor of psychiatry and Professor Fanqiang Meng, the Chinese clinical psychologist. At present, the headquarters of the US company is located in New Jersey, which is the capital of global pharmaceutical research and development, and the China headquarters is located in Shanghai, with more than 560 full-time employees, providing full clinical trial services for each phase of new drug research and development.
H&J has been deeply engaged in clinical trials for 20 years, undertook more than 1,000 clinical trials, and undertook more than 290 projects in the past two years, of which tumor and endocrine projects accounted for 70%. H&J has five core competitive advantages: department unity and cooperation to ensure rapid progress; Full-time expert team, grasp the right course; Co-construction and co-operating institutions, in-depth cooperation at the hospital level; Innovative operational tools (central static randomization system, CTMS-eTMF system, PK calculation and drug time curve generation system) to improve operational efficiency; Three-level quality control system to ensure the quality of the project.